Evaluation of high-mobility group box 1 protein concentration in serum of patients with M. tuberculosis infection

Immunological Investigations

Volumn 42, Issue 1, 2013, Pages 49-60

  Magryś, Agnieszka ^a   Paluch Oleś, Jolanta ^a   Kozioł Montewka, Maria ^a   Zaborowski, Tomasz ^a   Milanowski, Janusz ^a   Maciejewska, Barbara ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

HMGB1; M. tuberculosis; TNF; Tuberculosis

Indexed keywords

HIGH MOBILITY GROUP B1 PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BLOOD FLOW; CLINICAL EVALUATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; LATENT PERIOD; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL;

ADULT; AGED; BIOLOGICAL MARKERS; DISEASE PROGRESSION; FEMALE; HMGB1 PROTEIN; HUMANS; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PROGNOSIS; TUBERCULOSIS, PULMONARY; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84870927527     PISSN: 08820139     EISSN: 15324311     Source Type: Journal    
DOI: 10.3109/08820139.2012.723769     Document Type: Article

References (20)

1. American Thoracic Society. Medical Section of the American Lung Association (1999). Statement on Sarcoidosis. Am. J. Respir. Crit. Care Med. 160(2):736-755.
2. Anderson, V., Erlandsson-Harris, H., Yang, H., Tracey, K. J. (2002). HMGB1 as a DNAbinding cytokine. J. Leukoc. Biol. 72:1084-1091.
3. Bateman, E. D., Hurd, S. S., Barnes, P. J. (2008). Global strategy for asthma management and prevention: GINA executive summary. Eur. Respir. J. 31:142-178.
4. Bitto, A., Barone, M., David, A., Polito, F., Familiari, D., Monaco, F., Giardina, M., David, T., Messina, R., Noto, A., Di Stefano, V., Altavilla, D., Bonaiuto, A., Minutoli, L., Guarini, S., Ottani, A., Squadrito, F., Venuti, F. S. (2010). High mobility group box-1 expression correlates with poor outcome in lung injury patients. Pharmacol. Res. 61:116-120.
5. Centers for Disease Control and Prevention (2000). Diagnostic standards and classification of tuberculosis in adults and children. Am. J. Respir. Crit. Care Med. 61(4):1376-1395.
6. Centers for Disease Control and Prevention (2010) Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection - United States, 2010. MMWR 59(No. RR-5):1-25.
7. Cuncha, B. A. (2006). The atypical pneumonias: Clinical diagnosis and importance. Clin. Microbiol. Infect. 12 (Suppl. 3):12-24.
8. Dumitrin, I. E., Baruch, P., Manfredi, A. A., Bianchi, M. E., Rovere-Querini, P. (2005). HMGB1: Guiding immunity from within. Trends Immunol. 26:381-387.
9. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD (2011). Available from: Http://www.goldcopd. org/.
10. Grover, A., Taylor, J., Traudt, J., Keyser, A., Somerstedt, K., Schenkel, A., Izzo, A. A. (2008). Mycobacterial infection induces the secretion of high-mobility group box 1 protein. Cell Microbiol. 10:1390-1404.
11. Hou, C., Zhao, H., Lin, L., Li, W., Zhou, X., Lv, Y., Shen, X., Liang, Z., Cai, S., Zou, F. (2011). High Mobility Group Protein B 1 (HMGB1) in asthma: Comparison of patients with chronic obstructive pulmonary disease and healthy control. Mol. Med. 17(7-8):807-815.
12. Krzakowski, M., Orłowski, T., Roszkowski, K., Reinfuss, M., Olszewski, W., Ramlau, R., Kowalski, D., Konopa, K., Jassem, J., Jankowska, R., Kozielski, J., Wojtukiewicz, M., Drosik, K., Koralewski, P. (2007). Small-cell lung cancer. Diagnostic and therapeutic recommendations of Polish Cancer Group. Onkol. Prakt. Klin. 3(1):1-7.
13. Ledford, J. G., Lo, B., Kislan, M. M., Thomas, J. M., Evans, K., Cain, D. W., Kraft, M., Wiliams, K. L., Wright, J. R. (2010). Surfactant Protein-A inhibits Mycoplasmainduced dendritic cells maturation through regulation of HMGB1 cytokine activity. J. Immunol. 185:3884-3894.
14. Longo, D., Kasper, D. L., Jameson, J. L., Fauci, A. S., Hamser, S. L., Loscalzo, J. (2012). Harrison's Principles of Internal Medicine. Section 2. Chapter 258. Bronchiectosis and Lung Abscess. 18th Edition, the Mc Graw - Hill Companies Inc., USA.
15. Mootoo, A., Stylianou, E., Arias, M. A., Reljic, R. (2009). TNF-α in tuberculosis: A cytokine with a split personality. Inflamm. Allergy Drug Targets 8:53-62.
16. Naumnik, W., Nilklińska, W., Ossolińska, M., Chyczewska, E. (2009). Serum levels of HMGB1, survivin and VEGF in patients with advanced non-small cell lung cancer during chemotherapy. Folia Histochem. Cytobiol. 47(4):703-709.
17. Nocuń, M., Pałczyński, C (2008). HMGB1 as an inflammatory cytokine, potential target of novel anti-inflammatory therapy? Alergia Astma Immunol. 13:16-22.
18. Sims, G. P., Rowe, D. C., Rietdijk, S. T., Herbst, R., Coyle, A. J. (2010). HMGB1 and RANGE in inflammation and cancer. Annu. Rev. Immunol. 28: 367-388.
19. Wang, H., Vishnubhakat, J. M., Bloom, O., Zhang, M., Ombrellino, M., Sama, A., Tracey, K. J. (1999). Proinflammatory cytokines (tumor necrosis factor and interleukin 1) stimulate release of high mobility group protein-1 by pituicytes. Surgery 126:389-392.
20. Williams, J. H. H., Ireland, H. E. (2008). Sensing danger-hsp72 and HMGB1 as candidate signals. J. Leukoc. Biol. 83:489-492.